IRadimed Corporation develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets under the MRidium name; and MRI compatible patient vital signs monitoring system under the IRadimed name. The company also offers IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its MRI compatible products through direct sales force and independent distributors. IRadimed Corporation was incorporated in 1992 and is headquartered in Winter Springs, Florida.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IRMD
Previous Symbol
CUSIPN/A
Phone407-677-8022
Debt
Debt-to-Equity RatioN/A
Current Ratio8.36
Quick Ratio7.40
Price-To-Earnings
Trailing P/E Ratio317.38
Forward P/E Ratio65.10
P/E GrowthN/A
Sales & Book Value
Annual Sales$23.08 million
Price / Sales12.02
Cash Flow$0.2226 per share
Price / Cash114.05
Book Value$3.12 per share
Price / Book8.14
Profitability
EPS (Most Recent Fiscal Year)$0.08
Net Income$490,000.00
Net Margins16.59%
Return on Equity12.20%
Return on Assets10.32%
Miscellaneous
Employees83
Outstanding Shares10,930,000
Market Cap$268.65 million
OptionableNot Optionable
Iradimed (NASDAQ:IRMD) Frequently Asked Questions
What is Iradimed's stock symbol?
Iradimed trades on the NASDAQ under the ticker symbol "IRMD."
How will Iradimed's stock buyback program work?
Iradimed declared that its board has authorized a share buyback plan on Sunday, June 4th 2017, which authorizes the company to buyback $8,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to buy shares of its stock through open market purchases. Shares buyback plans are often a sign that the company's leadership believes its shares are undervalued.
How were Iradimed's earnings last quarter?
Iradimed Corp (NASDAQ:IRMD) released its earnings results on Tuesday, October, 30th. The medical equipment provider reported $0.14 EPS for the quarter, topping analysts' consensus estimates of $0.10 by $0.04. The medical equipment provider earned $7.62 million during the quarter, compared to the consensus estimate of $7.43 million. Iradimed had a net margin of 16.59% and a return on equity of 12.20%. View Iradimed's Earnings History.
When is Iradimed's next earnings date?
What guidance has Iradimed issued on next quarter's earnings?
Iradimed issued an update on its FY 2018 earnings guidance on Tuesday, October, 30th. The company provided earnings per share guidance of $0.50-0.51 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.47. The company issued revenue guidance of $30-30.2 million, compared to the consensus revenue estimate of $30.23 million.Iradimed also updated its Q4 2018 guidance to $0.12-0.13 EPS.
What price target have analysts set for IRMD?
2 equities research analysts have issued 1-year target prices for Iradimed's stock. Their forecasts range from $19.00 to $35.00. On average, they expect Iradimed's share price to reach $27.00 in the next year. This suggests a possible upside of 6.3% from the stock's current price. View Analyst Price Targets for Iradimed.
What is the consensus analysts' recommendation for Iradimed?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iradimed in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iradimed.
Has Iradimed been receiving favorable news coverage?
Media stories about IRMD stock have trended somewhat positive recently, InfoTrie reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Iradimed earned a media sentiment score of 0.6 on InfoTrie's scale. They also assigned media coverage about the medical equipment provider a news buzz of 7.0 out of 10, indicating that recent media coverage is likely to have an impact on the company's share price in the near term.
Are investors shorting Iradimed?
Iradimed saw a drop in short interest during the month of October. As of October 31st, there was short interest totalling 474,967 shares, a drop of 31.7% from the October 15th total of 695,779 shares. Based on an average daily volume of 146,238 shares, the days-to-cover ratio is presently 3.2 days. Approximately 10.1% of the company's shares are sold short. View Iradimed's Current Options Chain.
Who are some of Iradimed's key competitors?
Some companies that are related to Iradimed include Intersect ENT (XENT), SurModics (SRDX), OraSure Technologies (OSUR), AngioDynamics (ANGO), Cerus (CERS), Antares Pharma (ATRS), Anika Therapeutics (ANIK), LeMaitre Vascular (LMAT), Inovio Pharmaceuticals (INO), Neuronetics (STIM), Accuray (ARAY), SI-BONE (SIBN), Orthopediatrics (KIDS), Utah Medical Products (UTMD) and Nuvectra (NVTR).
Who are Iradimed's key executives?
Iradimed's management team includes the folowing people:
- Mr. Roger E. Susi, Founder, Chairman, CEO & Pres (Age 65)
- Mr. Christopher K. Scott, CFO & Sec. (Age 48)
- Mr. John McCreery, Chief Operating Officer (Age 63)
- Mr. Brent Johnson, Exec. VP of Worldwide Sales & Marketing (Age 59)
- Mr. Louis Waldman, Controller (Age 63)
Who are Iradimed's major shareholders?
Iradimed's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.09%), Mondrian Investment Partners LTD (1.09%), Cadence Capital Management LLC (0.68%), EAM Investors LLC (0.57%), Russell Investments Group Ltd. (0.53%) and EAM Global Investors LLC (0.38%). Company insiders that own Iradimed stock include Christopher K Scott, Francis X Casey, John K Mccreery, Louis S Waldman, Monty K Allen, Roger E Susi and Steven M Nardi. View Institutional Ownership Trends for Iradimed.
Which major investors are selling Iradimed stock?
IRMD stock was sold by a variety of institutional investors in the last quarter, including Cadence Capital Management LLC, Mondrian Investment Partners LTD and Russell Investments Group Ltd.. Company insiders that have sold Iradimed company stock in the last year include Christopher K Scott, Francis X Casey, John K Mccreery, Louis S Waldman, Monty K Allen and Steven M Nardi. View Insider Buying and Selling for Iradimed.
Which major investors are buying Iradimed stock?
IRMD stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., EAM Global Investors LLC, EAM Investors LLC, Engineers Gate Manager LP, Strs Ohio, Calamos Advisors LLC, Bank of New York Mellon Corp and O Shaughnessy Asset Management LLC. View Insider Buying and Selling for Iradimed.
How do I buy shares of Iradimed?
Shares of IRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Iradimed's stock price today?
One share of IRMD stock can currently be purchased for approximately $25.39.
How big of a company is Iradimed?
Iradimed has a market capitalization of $268.65 million and generates $23.08 million in revenue each year. The medical equipment provider earns $490,000.00 in net income (profit) each year or $0.08 on an earnings per share basis. Iradimed employs 83 workers across the globe.
What is Iradimed's official website?
How can I contact Iradimed?
Iradimed's mailing address is 1025 Willa Springs Dr., Winter Springs FL, 32708. The medical equipment provider can be reached via phone at 407-677-8022 or via email at [email protected]
MarketBeat Community Rating for Iradimed (NASDAQ IRMD)
MarketBeat's community ratings are surveys of what our community members think about Iradimed and other stocks. Vote "Outperform" if you believe IRMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
